Segment Reporting

12 Months Ended

Jun. 30, 2026

NOTE 4. SEGMENT REPORTING

Identification of reportable operating segments

Operating segments are reported in a manner consistent with internal reports which are reviewed and used by Management and the Board of Directors (who is identified as the Chief Operating Decision Makers (‘CODM’)). The Group operates in one operating segment, being Immunotherapy.


Operating segment information June 30, 2026	Immunotherapy A$			Unallocated A$		Consolidated A$
Revenue
License revenue		14,556,923			—		14,556,923
Other income
Research material sales		38,607			—		38,607
Grant income		5,338,572			—		5,338,572
Miscellaneous income		—			—		—
Net gain on foreign exchange		—			1,229,851		1,229,851
Interest income		—			3,005,047		3,005,047

Total revenue and other income		19,934,102			4,234,898		24,169,000

Result
Segment Result		(81,592,146	)		2,287,583		(79,304,563	)
Profit/(loss) before income tax expense		(81,592,146	)		2,287,583		(79,304,563	)
Income tax expense		—			—		—
Loss after income tax expense							(79,304,563	)

Total segment assets		83,267,229			—		83,267,229

Total segment liabilities		21,734,183			—		21,734,183


Operating segment information June 30, 2025	Immunotherapy A$			Unallocated A$		Consolidated A$
Revenue
License revenue		—			—		—
Other income
Research material sales		59,709			—		59,709
Grant income		4,974,823			—		4,974,823
Miscellaneous income		—			390		390
Net change on fair value movement		—			9,242		9,242
Interest income		—			5,287,209		5,287,209

Total revenue and other income		5,034,532			5,296,841		10,331,373

Result
Segment Result		(65,020,504	)		3,586,339		(61,434,165	)
Profit/(loss) before income tax expense		(65,020,504	)		3,586,339		(61,434,165	)
Income tax expense		—			—		—
Loss after income tax expense							(61,434,165	)

Total segment assets		156,983,434			—		156,983,434

Total segment liabilities		13,348,071			—		13,348,071


Operating segment information June 30, 2024	Immunotherapy A$			Unallocated A$		Consolidated A$
Revenue
License revenue		—			—		—
Other income
Research material sales		119,089			—		119,089
Grant income		3,722,788			—		3,722,788
Net gain on foreign exchange		—			113,458		113,458
Interest income		—			3,882,757		3,882,757

Total revenue and other income		3,841,877			3,996,215		7,838,092

Result
Segment Result		(46,556,929	)		3,840,304		(42,716,625	)
Profit/(loss) before income tax expense		(46,556,929	)		3,840,304		(42,716,625	)
Income tax expense		—			—		—
Loss after income tax expense							(42,716,625	)

Total segment assets		201,579,281			—		201,579,281

Total segment liabilities		12,057,539			—		12,057,539